Moderna says protection from its Covid-19 vaccine still strong six months on
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 17, 2022
TUESDAY, MAY 17, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Moderna says protection from its Covid-19 vaccine still strong six months on

Coronavirus chronicle

Reuters
14 April, 2021, 11:25 am
Last modified: 14 April, 2021, 11:35 am

Related News

  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot
  • 95% of target population fully vaccinated: Health Minister
  • Help all reach vaccination targets, Hasina urges COVAX summit
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety

Moderna says protection from its Covid-19 vaccine still strong six months on

The company has also started testing new versions of the vaccine that target a concerning new variant of the coronavirus, which was first identified in South Africa and is known as B.1.351

Reuters
14 April, 2021, 11:25 am
Last modified: 14 April, 2021, 11:35 am
Moderna says protection from its Covid-19 vaccine still strong six months on

Moderna Inc said on Tuesday that its Covid-19 vaccine still showed strong protection against the illness six months after people received their second shot, with efficacy of more than 90 percent against all cases of Covid-19 and more than 95 percent against severe Covid-19.

The vaccine maker, which will be updating investors on the progress of its vaccines at an event on Wednesday, said the six-month follow-up of its original late-stage study of the vaccine showed that vaccine efficacy remained consistent with its previous updates.

The company has also started testing new versions of the vaccine that target a concerning new variant of the coronavirus, which was first identified in South Africa and is known as B.1.351.

It said both versions of the vaccine that it is testing, including a multivalent vaccine that combines the newly designed vaccine with the previous one, increased neutralizing antibody titers against variants of concerns in mice, with the multivalent providing the broadest level of immunity.

The company in March began testing three approaches to boosting the vaccine in order to protect against new variants.

Moderna's vaccine is authorized or approved for use in more than 40 countries. It uses messenger RNA (mRNA) technology, which contains instructions for human cells to make proteins that mimic part of the coronavirus.

The instructions spur the immune system into action generating protective responses, but no actual virus is contained in the vaccines.

The Cambridge, Massachusetts-based company said that as of Monday it has delivered about 132 million doses globally, including 117 million doses for the United States. The company said it is on track to supply the nation with 300 million doses of the vaccine by the end of July.

Moderna said its supply chain outside the United States was established about a quarter behind the US supply chain and continues to ramp up.

The company said its average US selling price in the first quarter was around $15.40 per dose excluding a roughly $1 billion payment from the Biomedical Advanced Research and Development Authority, which is part of the US Department of Health and Human Services.

Outside the United States, prices ranged from $22 to $37 per dose, it said.

Top News / World+Biz

Moderna / Moderna Covid-19 Vaccine / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Are banks only gainers from dollar crisis?
    Are banks only gainers from dollar crisis?
  • PK Halder wants to return home
    PK Halder wants to return home
  • Exporters for continuation of 0.5% source tax for 5 years 
    Exporters for continuation of 0.5% source tax for 5 years 

MOST VIEWED

  • Customers wait in front of a restaurant in Beijing, China April 15, 2022. REUTERS/Tingshu Wang/Files
    China's economy skids as lockdowns hit factories, retailers
  • A medical worker in a protective suit collects a swab from a resident at a makeshift nucleic acid testing site inside a residential compound under lockdown, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China April 14, 2022. REUTERS/Xihao Jiang
    Shanghai aims for return to normal life from 1 June
  • South Korea's new President Yoon Suk-yeol signs a document as he works at the new Presidential office in Seoul, South Korea, May 10, 2022. Yonhap via REUTERS/File Photo
    S Korea says it will spare no effort to help North Korea amid Covid outbreak
  • North Korean leader Kim Jong Un wears a face mask amid the coronavirus disease (Covid-19) outbreak, while inspecting a pharmacy in Pyongyang, in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 15, 2022. KCNA via REUTERS
    Kim Jong Un orders North Korea military to 'stabilise' drug supply amid Covid outbreak
  • North Korea reports 15 more suspected Covid-19 deaths
    North Korea reports 15 more suspected Covid-19 deaths
  • Residents line up for nucleic acid tests during lockdown, amid the coronavirus disease (Covid-19) pandemic, in Shanghai, China, May 9, 2022. REUTERS/Aly Song
    Locked-down Shanghai to start gradually reopening malls, other businesses

Related News

  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot
  • 95% of target population fully vaccinated: Health Minister
  • Help all reach vaccination targets, Hasina urges COVAX summit
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety

Features

Bitcoin, by far the largest cryptocurrency, is a terrible substitute for government-issued money. Photo: Reuters

Crypto’s wild week offers a much-needed warning

10h | Panorama
Karst Stone Paper Journal: Write on indestructible stone paper

Karst Stone Paper Journal: Write on indestructible stone paper

11h | Brands
Pesky bugs do not stand a chance against this automatic indoor insect trap

Pesky bugs do not stand a chance against this automatic indoor insect trap

11h | Brands
Wazeenah: Turning furniture into a canvas

Wazeenah: Turning furniture into a canvas

11h | Brands

More Videos from TBS

Finland, Sweden decide to join NATO

Finland, Sweden decide to join NATO

2h | Videos
Where you can swim for Tk5

Where you can swim for Tk5

4h | Videos
Cultural activists pay tribute to Hassan Arif

Cultural activists pay tribute to Hassan Arif

7h | Videos
How PK Halder becomes a scamster

How PK Halder becomes a scamster

7h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

4
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

5
Union Capital asked to return Tk100cr FDR to BATBC 
Banking

Union Capital asked to return Tk100cr FDR to BATBC 

6
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab